Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Strong
Telephone
61.2.9256.2505
Address
Level 23 180 George Street Salesforce Tower Sydney, New South Wales (NSW) 2000
Description
Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. It produces antibiotics that are effective in attacking disease-causing Gram-positive and Gram-negative bacteria. The company was founded on April 11, 2007 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.41 - 0.69
Trade Value (12mth)
AU$21,834.00
1 week
3.03%
1 month
6.25%
YTD
-2.86%
1 year
-23.12%
All time high
1.86
EPS 3 yr Growth
14.60%
EBITDA Margin
N/A
Operating Cashflow
-$13m
Free Cash Flow Return
0.00%
ROIC
0.00%
Interest Coverage
-25.60
Quick Ratio
0.30
Shares on Issue (Fully Dilluted)
204m
HALO Sector
Healthcare
Next Company Report Date
29-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
30 August 24 |
Preliminary Final Report
×
Preliminary Final Report |
30 August 24 |
Annual Report to Shareholders
×
Annual Report to Shareholders |
30 August 24 |
Appendix 4G
×
Appendix 4G |
06 August 24 |
Application for quotation of securities - RCE
×
Application for quotation of securities - RCE |
06 August 24 |
Securities Trading Policy
×
Securities Trading Policy |
05 August 24 |
Successful Completion of Share Purchase Plan
×
Successful Completion of Share Purchase Plan |
26 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
15 July 24 |
US Department of Defense Grants US $2m for R327G
×
US Department of Defense Grants US $2m for R327G |
11 July 24 |
Change of Auditor
×
Change of Auditor |
10 July 24 |
Share Purchase Plan - Letter and Offer Booklet
×
Share Purchase Plan - Letter and Offer Booklet |
09 July 24 |
Application for quotation of securities - RCE
×
Application for quotation of securities - RCE |
09 July 24 |
Cleansing Notice
×
Cleansing Notice |
08 July 24 |
R327 Efficacy against WHO Priority Pathogen Acinetobacter B
×
R327 Efficacy against WHO Priority Pathogen Acinetobacter B |
02 July 24 |
Placement & SPP to raise $10 million - Funded to FY26
×
Placement & SPP to raise $10 million - Funded to FY26 |
02 July 24 |
Proposed issue of securities - RCE
×
Proposed issue of securities - RCE |
02 July 24 |
Equity Raising Presentation
×
Equity Raising Presentation |
01 July 24 |
Clarification - Phase I/II UTI/Urosepsis Fast Infusion Trial
×
Clarification - Phase I/II UTI/Urosepsis Fast Infusion Trial |
01 July 24 |
Trading Halt
×
Trading Halt |
28 June 24 |
Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
×
Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete |
24 June 24 |
Ethics Approval Broadens to All Topical Infections
×
Ethics Approval Broadens to All Topical Infections |
18 June 24 |
R327 added to WHO List of Antibacterial Products
×
R327 added to WHO List of Antibacterial Products |
18 June 24 |
Further R&D Rebate Approved
×
Further R&D Rebate Approved |
11 June 24 |
Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
×
Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial |
03 June 24 |
Military Health Research Symposium Abstract & Presentation
×
Military Health Research Symposium Abstract & Presentation |
15 May 24 |
Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort
×
Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.